Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Avitide, founded in 2012 and based in Lebanon, New Hampshire, is a specialized company focusing on affinity purification solutions. The company's flagship product, AVIPure affinity resins, offers efficient processing for various custom and platform applications, addressing purification challenges across a broad spectrum of biopharmaceuticals. Avitide serves industries requiring high-quality bioprocessing and purification technologies, including those involved in enzyme, antibody, and vaccine production.
Since its inception, Avitide has demonstrated significant growth, having raised a total of $40.93 million in funding. This financial backing suggests investor confidence in the company's innovative approach to bioprocessing solutions. In a notable development, Avitide was acquired by Repligen in September 2021, potentially impacting any future plans for an initial public offering (IPO).
Given the company's acquisition by Repligen, the prospects of an Avitide IPO are uncertain. As we don't have specific news or reports about Avitide's IPO plans, we cannot provide any concrete information or predictions about the company going public. It's important to note that the acquisition may have altered any previous considerations for an IPO.
Investors interested in the bioprocessing and purification technology sector may want to keep an eye on Avitide's parent company, Repligen, for potential investment opportunities. However, as always, it's crucial to conduct thorough research and consult with financial advisors before making any investment decisions.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Avitide's IPO prospects remain uncertain, investors eager to gain exposure to innovative biotech companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies, including potential leaders in the biotechnology sector. Our platform allows you to diversify your portfolio with lower minimum investments, potentially benefiting from the growth of emerging industry pioneers like Avitide before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
